Literature DB >> 34269917

Acquisition, Processing, and Interpretation of PET 18F-FDG Viability and Inflammation Studies.

Emel Celiker-Guler1, Terrence D Ruddy1, R Glenn Wells2.   

Abstract

PURPOSE OF REVIEW: This article reviews the acquisition protocols and image interpretation for 18F-fluorodeoxyglucose (18F-FDG) imaging with positron emission tomography (PET) applied to the evaluation of myocardial viability and inflammation. RECENT
FINDINGS: Cardiac PET with 18F-FDG provides essential information for the assessment of myocardial viability and inflammation and is usually combined with PET perfusion imaging using 82Rb or 13N-ammonia. Viable myocardium maintains glucose metabolism which can be detected via the uptake of 18F-FDG by PET imaging. The patient is prepared for viability imaging by shifting the metabolism of the heart to maximize the uptake of glucose and hence of 18F-FDG. Comparison of the 18F-FDG and myocardial perfusion images allows distinction between regions of the myocardium that are hibernating and thus may recover function with intervention, from those that are infarcted. Increased glucose utilization in the inflammatory cells also makes 18F-FDG a useful imaging technique in conditions such as cardiac sarcoidosis. Here, suppression of normal myocardial uptake is essential for accurate image interpretation. 18F-FDG PET broadens the scope of information potentially available through a cardiac PET study. With careful patient preparation, it provides valuable insights into myocardial viability and inflammatory processes such as sarcoidosis.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Myocardial inflammation; Myocardial viability; PET FDG

Mesh:

Substances:

Year:  2021        PMID: 34269917     DOI: 10.1007/s11886-021-01555-7

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  47 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

2.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  J Am Coll Cardiol       Date:  2017-04-28       Impact factor: 24.094

3.  Absolute blood flow and oxygen consumption in stunned myocardium in patients with coronary artery disease.

Authors:  Edward Barnes; Roger J C Hall; David P Dutka; Paolo G Camici
Journal:  J Am Coll Cardiol       Date:  2002-02-06       Impact factor: 24.094

4.  Myocardial blood flow, function, and metabolism in repetitive stunning.

Authors:  M F Di Carli; P Prcevski; T P Singh; J Janisse; J Ager; O Muzik; R Vander Heide
Journal:  J Nucl Med       Date:  2000-07       Impact factor: 10.057

5.  Myocardial viability and survival in ischemic left ventricular dysfunction.

Authors:  Robert O Bonow; Gerald Maurer; Kerry L Lee; Thomas A Holly; Philip F Binkley; Patrice Desvigne-Nickens; Jaroslaw Drozdz; Pedro S Farsky; Arthur M Feldman; Torsten Doenst; Robert E Michler; Daniel S Berman; Jose C Nicolau; Patricia A Pellikka; Krzysztof Wrobel; Nasri Alotti; Federico M Asch; Liliana E Favaloro; Lilin She; Eric J Velazquez; Robert H Jones; Julio A Panza
Journal:  N Engl J Med       Date:  2011-04-04       Impact factor: 91.245

6.  Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis.

Authors:  Kevin C Allman; Leslee J Shaw; Rory Hachamovitch; James E Udelson
Journal:  J Am Coll Cardiol       Date:  2002-04-03       Impact factor: 24.094

7.  F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2).

Authors:  Rob S B Beanlands; Graham Nichol; Ella Huszti; Dennis Humen; Normand Racine; Michael Freeman; Karen Y Gulenchyn; Linda Garrard; Robert deKemp; Ann Guo; Terrence D Ruddy; Francois Benard; André Lamy; Robert M Iwanochko
Journal:  J Am Coll Cardiol       Date:  2007-10-10       Impact factor: 24.094

8.  Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function.

Authors:  Rob S B Beanlands; Terrence D Ruddy; Robert A deKemp; Robert M Iwanochko; Geoffrey Coates; Michael Freeman; Claude Nahmias; Paul Hendry; Robert J Burns; Andre Lamy; Lynda Mickleborough; William Kostuk; Ernest Fallen; Graham Nichol
Journal:  J Am Coll Cardiol       Date:  2002-11-20       Impact factor: 24.094

Review 9.  Hibernating myocardium: diagnosis and patient outcomes.

Authors:  Arend F L Schinkel; Jeroen J Bax; Don Poldermans; Abdou Elhendy; Roberto Ferrari; Shahbudin H Rahimtoola
Journal:  Curr Probl Cardiol       Date:  2007-07       Impact factor: 5.200

Review 10.  The stunned myocardium: prolonged, postischemic ventricular dysfunction.

Authors:  E Braunwald; R A Kloner
Journal:  Circulation       Date:  1982-12       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.